Delcath Systems, Inc. - PDFSEARCH.IO - Document Search Engine

Delcath Systems, Inc.
Results: 7

#	Item
1	Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Wen-Jen Hwu, M.D., Ph.D. Committee: Oncologic Drugs Advisory Add to Reading List Source URL: www.fda.gov Language: English Food and Drug Administration Medicine Delcath Systems Inc. Hepatology
2	DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Add to Reading List Source URL: www.fda.gov Language: English Delcath Systems Inc. Uveal melanoma DecisionDx-UM Medicine Melanoma Cancer organizations
3	FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 2, 2013 NDA[removed] – 001 Melblez Kit Delcath Systems, Inc. Add to Reading List Source URL: www.fda.gov Language: English Delcath Systems Inc. Hepatocellular carcinoma Uveal melanoma Ipilimumab Immunotherapy End point of clinical trials DecisionDx-UM Sunitinib Medicine Hepatology Melanoma
4	Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Takami Sato, M.D., Ph.D. Committee: Oncologic Drugs Advisory Add to Reading List Source URL: www.fda.gov Language: English Medicine Delcath Systems Inc. Hepatology
5	Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned James C. Yao, Diane Reidy Lagunes and Matthew H. Kulke The Oncologist published online April 24, 2013 Downloaded from http Add to Reading List Source URL: www.carcinoid.org Language: English - Date: 2013-04-30 13:14:03 Sunitinib Everolimus Carcinoid Octreotide Treatment and prognosis of renal cell carcinoma Delcath Systems Inc. Medicine Oncology Neuroendocrine tumor
6	Clinical Practice Guideline Add to Reading List Source URL: www.albertahealthservices.ca Language: English - Date: 2013-08-26 17:07:30 Amides Cancer treatments Ipilimumab Vemurafenib Bevacizumab Dacarbazine Temozolomide Immunotherapy Delcath Systems Inc. Medicine Pharmacology Melanoma
7	Mirna Therapeutics Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting --MRX34 found to have manageable safety profile during initial dose-escalation phase of clinical trial in pa Add to Reading List Source URL: mirnarx.com Language: English - Date: 2014-04-08 15:32:40 Hepatology Hepatocellular carcinoma Delcath Systems Inc. MicroRNA RNA Biology

UPDATE